Loading…
NuCana plc is projected to decline to $1.34 by 2027, a -1% move from its current price of $1.35. NCNA is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 8/4/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Aug 5 | $1.30 | $1.35 | $1.41 | -0.03% |
| Aug 6 | $1.27 | $1.35 | $1.43 | -0.06% |
| Aug 7 | $1.26 | $1.35 | $1.45 | -0.09% |
| Aug 8 | $1.24 | $1.35 | $1.46 | -0.12% |
| Aug 9 | $1.23 | $1.35 | $1.48 | -0.15% |
| Aug 10 | $1.22 | $1.35 | $1.49 | -0.18% |
| Aug 11 | $1.21 | $1.35 | $1.50 | -0.21% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $1.21 | $1.35 | $1.50 | -0.21% |
| Week 2 | $1.15 | $1.34 | $1.57 | -0.42% |
| Week 3 | $1.11 | $1.34 | $1.62 | -0.62% |
| Week 4 | $1.08 | $1.34 | $1.66 | -0.83% |
| Week 5 | $1.05 | $1.34 | $1.70 | -1.04% |
| Week 6 | $1.02 | $1.33 | $1.74 | -1.24% |
| Week 7 | $1.00 | $1.33 | $1.77 | -1.45% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
NuCana plc is a clinical-stage biopharmaceutical company that develops medicines to treat patients with cancer in the United States. It applies its ProTide technology to transform prescribed chemotherapy agents and nucleoside analogs into medicines. The company’s pipeline includes NUC-3373, derived from the nucleoside analog 5-fluorouracil, in Phase 1b/2 in metastatic colorectal cancer and in other colorectal cancer settings, as well as NUC-7738, a ProTide transformation of 3′-deoxyadenosine in Phase 2 of a Phase 1/2 trial for advanced solid tumors.
NuCana has an assignment, license, and collaboration agreement with Cardiff ProTides Ltd to discover, design drugs, and screen purine and pyrimidine-based nucleosides as potential candidates. The company was incorporated in 1997 and is based in Edinburgh, the United Kingdom. It was formerly known as NuCana BioMed Limited and changed its name to NuCana plc in August 2017.
NuCana plc (NCNA) operates in the Healthcare sector. The stock is currently priced at $1.32 and sits with a market capitalization of $5.49M, ranking 5254 by market scope. The current price and market position reflect a small-cap biotechnology profile with ongoing clinical-stage programs.
The forecast provided spans multiple years and shows a path of fluctuating but ultimately rising average prices through 2050, with varying minimums and maximums by year. The outlook indicates symmetry around mid-term levels before a more pronounced rise toward 2050.
A major floor 42.2% below — a decisive break under it would weaken the trend.
The nearest floor, 10.4% below — buyers have tended to step in here.
The nearest ceiling, 41.5% above — a clean break opens room to run.
A major ceiling 72.6% above — clearing it would confirm fresh momentum.
Key NCNA support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of NCNA market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $1.27 | Buy | $1.28 | Buy |
| MA 10 | $1.29 | Buy | $1.29 | Buy |
| MA 20 | $1.31 | Buy | $1.35 | Sell |
| MA 50 | $1.66 | Sell | $1.57 | Sell |
| MA 100 | $1.80 | Sell | $2.35 | Sell |
| MA 200 | $2.58 | Sell | $22.83 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 43.00 | Neutral |
| Stoch RSI (14) | 100.00 | Sell |
| CCI (20) | 20.24 | Neutral |
| Williams %R (14) | -26.67 | Info |
| MACD (12,26,9) | 0.02 | Buy |
| ROC (12) | -2.22 | Sell |
| Bollinger %B (20,2) | 0.56 | Neutral |
| Stochastic %K (14) | 73.33 | Neutral |
| TRIX (15) | -1.17 | Sell |
| Awesome (5,34) | -0.20 | Sell |
| Ultimate (7,14,28) | 44.91 | Neutral |
| Momentum (10) | 0.00 | Buy |
| Aroon Osc (25) | -92.00 | Sell |
| Hull MA (9) | 1.25 | Buy |
| ADX (14) | 28.50 | Sell |
| ATR (14) | 0.05 | Info |
In the near term, the 30-day technical picture is mixed with NEUTRAL sentiment. The RSI(14) sits at 40, suggesting modest momentum, while the 50-day simple moving average is $1.66 and the 200-day simple moving average is $2.58. A key near-term price zone exists between a support of $1.21 and a resistance of $1.91.
Over the last 30 days, the price has traded within a range from $1.01 to $1.73, reflecting a narrower swing relative to longer-term volatility. The stock’s annualized volatility stands around 80%, underscoring substantial price fluctuations and higher risk relative to broader markets.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $1.21 | $1.35 | $1.65 | 0% | Neutral | |
| $1.02 | $1.34 | $1.88 | -1% | Neutral | |
| $1.08 | $1.49 | $2.20 | +10% | Neutral | |
| $1.31 | $1.86 | $2.88 | +38% | Bullish | |
| $1.20 | $1.77 | $2.82 | +31% | Bullish | |
| $1.03 | $1.57 | $2.58 | +16% | Neutral | |
| $1.13 | $1.76 | $2.97 | +31% | Bullish | |
| $0.979 | $1.57 | $2.71 | +16% | Neutral | |
| $0.9482 | $1.56 | $2.75 | +16% | Neutral | |
| $1.25 | $2.12 | $3.80 | +57% | Bullish | |
| $1.17 | $2.22 | $4.32 | +64% | Bullish | |
| $2.11 | $4.69 | $10.25 | +247% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| August 2026 | $1.21 | $1.35 | $1.71 | +0.00% |
| September 2026 | $1.18 | $1.41 | $1.76 | +4.74% |
| October 2026 | $1.08 | $1.31 | $1.66 | -7.09% |
| November 2026 | $1.03 | $1.26 | $1.61 | -4.14% |
| December 2026 | $1.04 | $1.28 | $1.65 | +1.47% |
Click any year to see its month-by-month NCNA forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
By 2026, NCNA could reach as high as $1.65, with a base case around $1.35 and support toward $1.21 — roughly 0% from $1.35. A consolidation phase looks the most probable path here.
Expect NCNA to range from $1.02 to $1.88 through 2027. The $1.34 average target implies a -1% move from current prices. That is -1% versus the projected 2026 average. Price action looks broadly range-bound.
The NCNA price prediction for 2028 points to an average of $1.49 (low $1.08, high $2.20) — a potential gain of +10% on today's $1.35. A consolidation phase looks the most probable path here.
In 2029, NCNA is projected to trade between $1.31 and $2.88, averaging $1.86 — a potential gain of +38% from today's $1.35. That is up +25% on the projected 2028 average. Momentum favours further upside here.
NuCana plc's 2030 outlook centres on $1.77, within a $1.20 to $2.82 range. That is -5% versus the projected 2029 average. That marks a +31% change versus current levels. Buyers look set to stay in control over this stretch.
By 2031, NCNA could reach as high as $2.58, with a base case around $1.57 and support toward $1.03 — roughly +16% from $1.35. Price action looks broadly range-bound.
Expect NCNA to range from $1.13 to $2.97 through 2032. The $1.76 average target implies a +31% move from current prices. That is up +12% on the projected 2031 average. Buyers look set to stay in control over this stretch.
The NCNA price prediction for 2033 points to an average of $1.57 (low $0.979, high $2.71) — a potential gain of +16% on today's $1.35. Price action looks broadly range-bound.
In 2034, NCNA is projected to trade between $0.9482 and $2.75, averaging $1.56 — a potential gain of +16% from today's $1.35. That is -1% versus the projected 2033 average. A consolidation phase looks the most probable path here.
NuCana plc's 2035 outlook centres on $2.12, within a $1.25 to $3.80 range. That is up +35% on the projected 2034 average. That marks a +57% change versus current levels. Momentum favours further upside here.
By 2040, NCNA could reach as high as $4.32, with a base case around $2.22 and support toward $1.17 — roughly +64% from $1.35. Buyers look set to stay in control over this stretch.
Expect NCNA to range from $2.11 to $10.25 through 2050. The $4.69 average target implies a +247% move from current prices. That is up +111% on the projected 2040 average. Momentum favours further upside here.
Investing $1,000 in NCNA today (≈ 740.740741 NCNA) could be worth
$3,472.72
+$2,472.72 (+247%) by 2050 · US Dollar
Based on the average projected NCNA price of $4.69 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in NCNAwould be worth at today's price.
$1,000 invested in NCNA on Jul 31, 2025 (≈ 116.279065 NCNA) would be worth
$156.98
-$843.02 (-84.3%) today · 0.16× · US Dollar
Based on a NCNA entry price of $8.6 vs. today's $1.35.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $1.29 | $1,046.51 | +4.7% |
| 1 month ago | $1.44 | $937.5 | -6.3% |
| 3 months ago | $2.25 | $600 | -40.0% |
| 6 months ago | $2.58 | $523.26 | -47.7% |
| 1 year ago | $8.6 | $156.98 | -84.3% |
| All time (5.0y) ago | $10,250 | $0.13 | -100.0% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our NCNA forecast.
Our base-case forecast reaches $2.70 around 2050.
Implied market cap at $2.70: $11.24M
The multi-year forecast for NuCana shows a trajectory of gradual appreciation with notable bullish inflection points later in the horizon. The 2026 forecast shows an average of $1.32 with a range from $1.21 to $1.62, and neutral sentiment. By 2029 the average is $1.82 with a bullish tilt and a 38.1 ROI, moving to 2030 with an average of $1.73 and a bullish stance, ROI 30.7.
The outlook then extends through 2032 (avg $1.73, ROI 30.7) and 2035 (avg $2.07, ROI 57.1) with bullish sentiment. In 2040 the average price is forecast at $2.17 and a 64.7 ROI while remaining bullish. The pinnacle year 2050 projects an average of $4.58 and a substantial 247.3 ROI with bullish sentiment, supported by a range that extends to $10.02 and a high of $10.02.
Across the horizon, the forecast includes years with neutral or bullish sentiment and an occasional negative short-term ROI (for example, 2027 shows ROI -1), underscoring the uncertainty and variability inherent in price projections. Overall, the long-term view points to meaningful upside potential into 2050, but it remains contingent on clinical, regulatory, and market dynamics that could diverge from these estimates.
Tap a question to reveal the answer.
In 2030 the forecast shows an average price of $1.73, with a minimum of $1.17 and a maximum of $2.75; ROI 30.7; sentiment BULLISH.
Yes. The 2050 forecast has an average of $4.58, a minimum of $2.06, and a maximum of $10.02, with ROI 247.3 and a BULLISH sentiment.
Current price is $1.32 and market capitalization is $5.49M.
For 2029, the forecast shows min $1.28, avg $1.82, max $2.81, ROI 38.1, sentiment BULLISH.
Yes. The 2027 forecast shows ROI -1, reflecting a negative ROI in that year, while other years show positive ROI with varying levels.
NuCana plc Community Discussion
0Share your NuCana plc price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.